<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913481</url>
  </required_header>
  <id_info>
    <org_study_id>ANH/35/OSR</org_study_id>
    <nct_id>NCT03913481</nct_id>
  </id_info>
  <brief_title>Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.</brief_title>
  <acronym>ANH</acronym>
  <official_title>Acute Normovolemic Hemodilution in High-risk Cardiac Surgery Patients. A Multicentre Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Vita-Salute San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università Vita-Salute San Raffaele</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transfusions are one of the most overused treatments in modern medicine, and saving blood is
      one important issue all around the world. Cardiac surgery makes up a large percentage of the
      overall blood components consumption in surgery.

      Acute normovolemic hemo-dilution (ANH) is a well-known strategy which has been used for years
      without the support of high quality evidence based medicine to improve post-cardiopulmonary
      bypass coagulation and reduce red blood cells (RBC) transfusion. We designed a multicenter
      randomized controlled trial to investigate the effect of ANH in reducing the number of
      cardiac surgery patients receiving RBC transfusions during hospital stay. We will randomize
      2000 patients to have sufficient power to demonstrate a 20% relative and 7% absolute risk
      reduction in the number of patients' RBC transfusion. If the results of the study will
      confirm our hypothesis, this will have a great impact on blood management in cardiac
      operating room.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RBCs transfusion</measure>
    <time_frame>hospital discharge, an average of 10 days</time_frame>
    <description>The number of patients receiving RBCs transfusion after elective cardiac surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>30-day mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>hospital discharge, an average of 10 days</time_frame>
    <description>Amount of blood components (RBC, fresh frozen plasma-FFP, platelet -PLT) transfused (units/ml)
Estimated total blood volume lost (ml) at 12 hours after surgery
Surgical revision for bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic complications</measure>
    <time_frame>hospital discharge,an average of 10 days</time_frame>
    <description>Myocardial infarction
Stroke
Thromboembolic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AKI</measure>
    <time_frame>hospital discharge, an average of 10 days</time_frame>
    <description>Developing of acute kidney injury</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>C.Surgical Procedure; Cardiac</condition>
  <arm_group>
    <arm_group_label>ANH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Best available treatments plus ANH, performed withdrawing a volume of blood before the CPB. The volume will be personalized for every patient, but it'll be at least 650ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No ANH</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acute normovolemic hemodilution</intervention_name>
    <description>In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.</description>
    <arm_group_label>ANH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Best available treatment without ANH</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Any cardiac surgical intervention on CPB

          -  Elective surgery

        Exclusion Criteria:

          -  Medical decision (e.g.: planned pre-CPB ANH considered undeniable for ethical reasons
             or not applicable for safety issues)

          -  Unstable Coronary Artery Disease: Recent (&lt; 6 weeks) myocardial infarction, unstable
             angina, severe (&gt; 70%) left main coronary artery stenosis

          -  Critical preoperative state (ventricular tachycardia or ventricular fibrillation or
             aborted sudden death, preoperative cardiac massage, preoperative ventilation before
             anesthetic room, hemodynamic instability, preoperative inotropes or IABP, preoperative
             severe acute renal failure (anuria or oliguria &lt;10ml/hr.)

          -  Emergency surgery

          -  Pregnancy

          -  Unfeasibility to withdraw ≥ 650 ml without inducing hemodynamic instability

          -  Unfeasibility to withdraw ≥ 650 ml without inducing pre-CPB anemia (Htc &lt;30%)

          -  Unfeasibility to withdraw ≥ 650 ml without inducing low Htc during CPB (Htc &lt;24%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Zangrillo, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Vita-Salute University of Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanni Landoni, Prof</last_name>
    <phone>+39022643</phone>
    <phone_ext>6151</phone_ext>
    <email>landoni.giovanni@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Raffaele di Milano, Italy</name>
      <address>
        <city>Milano</city>
        <state>Milano, Italy</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Landoni, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Fabrizio Monaco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università Vita-Salute San Raffaele</investigator_affiliation>
    <investigator_full_name>Giovanni Landoni</investigator_full_name>
    <investigator_title>MD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>tissue</keyword>
  <keyword>organ and systemic injury responses to surgery</keyword>
  <keyword>trauma</keyword>
  <keyword>burn</keyword>
  <keyword>sepsis</keyword>
  <keyword>hemorrhage</keyword>
  <keyword>ischemia- reperfusion</keyword>
  <keyword>resuscitation</keyword>
  <keyword>including integrating pathways and signals</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>transfusion</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

